CTLA4 and melanoma: Studies conducted by Van Allen et al. as well as Rizvy et al. demonstrate that a high TMB and elevated neo-antigen expression were significantly correlated with responses to anti-PDL1 treatment in NSCLC and to anti-CTLA-4 treatment in melanoma [41,42,43].